The Use of ATP-MgCl2 in the Treatment of Injury and Shock.
Abstract
The purpose of our studies was to determine the hemodynamic responses to ATP-Magnesium chloride (MgC12) in conscious dogs and primates. ATP-MgC12 infusion into normovolemic and hypovolemic dogs produced a decrease in systemic vascular resistance, an increase in cardiac output and a decrease in heart rate. This combination of effects would be particularly beneficial to the hypovolemic patient. Our objectives were to also determine the safety and hemodynamic response of ATP-MgC12 infusion in normal awake human volunteers. Five healthy adult male volunteers received an intravenous infusion of ATP-MgC12 on four separate occasions. Hemodynamic measurements were made at end exhalation in the supine position and included heart rate and systolic, diastolic and mean blood pressure. Cardiac output was determined by injection of indocyanine green and measured by the principle of earpiece densitometry. Measurements were made prior to infusion, at 5 minute intervals during infusion and following termination of the infusion. Blood samples were obtained for determination of hemoglobin, sodium, potassium and glucose. Stroke volume index (SVI) and total systemic resistance (TSR) were derived from standard formulae. The results indicated that cardiac output increased by 76% from control values with ATP-MgC12 infusion. This increase in cardiac output correlated positively with ATP-MGC12 infusion rate. This was paralleled by a 45% increase in heart rate. SVI increased by 14%, however, the mean blood pressure did not change significantly over the entire range of infusion rates. ATP-MgC12 is a potent vasodilator.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 30, 1985
- Accession Number
- ADA187340
Entities
People
- Arthur E. Baue
- Irshad H. Chaudry
Organizations
- Yale University